| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
1 C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for... |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Protein degraded. Disease targeted. Lives transformed. September 2026 Exhibit 99.2 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Amendment No. 2 to the 2020 Stock Option and Incentive Plan In accordance with Section 16 of C4 Therapeutics, Inc. (the “Company”) 2020 Stock Option and Incentive Plan (the “Plan”), the Plan is hereby amended as follows, subject to appro... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Protein degraded. Disease targeted. Lives transformed. June 2026 |
| 15 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 12, 2026, C4 Therapeutics, Inc. (the “Company”) determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026. Mr. Mossler’s departure from the Company is not due to any disagr... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab |
| 10 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
AMENDMENT NO. 1 TO THE SECOND AMENDED AND RESTATED BY-LAWS OF C4 THERAPEUTICS, INC. (the “Corporation”) Section 8 of Article VI of the Second Amended and Restated By-laws of the Corporation (the “By-laws”) is hereby amended and restated ... |
| 09 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Protein degraded. Disease targeted. Lives transformed. April 2026 |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds |
| 16 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
Introductory. C4 Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 21,895,000 shares (the “Shares”) of its comm... |
| 16 Oct 2025 |
8-K: Other Events
Protein degraded. Disease targeted. Lives transformed. October 2025 |
| 01 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma |
| 22 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Updated Data From Phase 1 Trial of Cemsidomide in Multiple Myeloma & Next Steps International Myeloma Society (IMS) Annual Meeting September 2025 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation |
| 18 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Delaware The First State Page 1 5840223 8100 Authentication: 203978031 SR# 20253108061 Date: 06-18-25 You may verify this certificate online at corp.delaware.gov/authver.shtml I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal... |
| 14 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 10, 2025, Bruce Downey notified the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to retire from the Board and not to stand for reelection at the 2025 Annual Meeting of Stockholders. ... |
Loading...